Great Novel Therapeutics Biotech & Medicals
Taipei Exchange 7427.TWO
Great Novel Therapeutics Biotech & Medicals Free Cash Flow for the year ending December 31, 2023: USD -2.42 M
Great Novel Therapeutics Biotech & Medicals Free Cash Flow is USD -2.42 M for the year ending December 31, 2023, a 5.47% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.
-
Great Novel Therapeutics Biotech & Medicals Free Cash Flow for the year ending December 31, 2022 was USD -2.56 M, a -14.48% change year over year.
-
Great Novel Therapeutics Biotech & Medicals Free Cash Flow for the year ending December 31, 2021 was USD -2.23 M, a -14.34% change year over year.
-
Great Novel Therapeutics Biotech & Medicals Free Cash Flow for the year ending December 31, 2020 was USD -1.95 M, a -215.73% change year over year.
-
Great Novel Therapeutics Biotech & Medicals Free Cash Flow for the year ending December 31, 2019 was USD -618.76 K.
Key data
| Date | Free Cash Flow | Operating Cash Flow | Net Cash Used For Investing Activities | Net Cash Used Provided By Financing Activities |
|---|
Market news
Loading...
Taipei Exchange: 7427.TWO
| CEO | Dr. Chia-Nan Chen |
| IPO Date | July 8, 2021 |
| Location | |
| Headquarters | No.508, Zhongxiao East Road |
| Employees | 19 |
| Sector | Health Care |
| Industries | |
Description
Great Novel Therapeutics Biotech & Medicals engages in the development of drugs for the treatment of advanced and refractory cancers. It develops drugs for cancer immunotherapy, including tumor microenvironment regulators, epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors. The company was formerly known as GNT Biotech & Medicals Corporation. Great Novel Therapeutics Biotech & Medicals was founded in 2013 and is based in Taipei City, Taiwan.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email